These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 21402842)

  • 1. Use of a selective inhibitor to define the chemotherapeutic potential of the plasmodial hexose transporter in different stages of the parasite's life cycle.
    Slavic K; Delves MJ; Prudêncio M; Talman AM; Straschil U; Derbyshire ET; Xu Z; Sinden RE; Mota MM; Morin C; Tewari R; Krishna S; Staines HM
    Antimicrob Agents Chemother; 2011 Jun; 55(6):2824-30. PubMed ID: 21402842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Life cycle studies of the hexose transporter of Plasmodium species and genetic validation of their essentiality.
    Slavic K; Straschil U; Reininger L; Doerig C; Morin C; Tewari R; Krishna S
    Mol Microbiol; 2010 Mar; 75(6):1402-13. PubMed ID: 20132450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of Selective Inhibitors of the Plasmodium falciparum Hexose Transporter PfHT by Screening Focused Libraries of Anti-Malarial Compounds.
    Ortiz D; Guiguemde WA; Johnson A; Elya C; Anderson J; Clark J; Connelly M; Yang L; Min J; Sato Y; Guy RK; Landfear SM
    PLoS One; 2015; 10(4):e0123598. PubMed ID: 25894322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Why is the Plasmodium falciparum hexose transporter a promising new drug target?
    Joët T; Morin C; Fischbarg J; Louw AI; Eckstein-Ludwig U; Woodrow C; Krishna S
    Expert Opin Ther Targets; 2003 Oct; 7(5):593-602. PubMed ID: 14498822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation of the hexose transporter of Plasmodium falciparum as a novel drug target.
    Joet T; Eckstein-Ludwig U; Morin C; Krishna S
    Proc Natl Acad Sci U S A; 2003 Jun; 100(13):7476-9. PubMed ID: 12792024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A constitutive pan-hexose permease for the Plasmodium life cycle and transgenic models for screening of antimalarial sugar analogs.
    Blume M; Hliscs M; Rodriguez-Contreras D; Sanchez M; Landfear S; Lucius R; Matuschewski K; Gupta N
    FASEB J; 2011 Apr; 25(4):1218-29. PubMed ID: 21169382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of druggable small molecule antagonists of the Plasmodium falciparum hexose transporter PfHT and assessment of ligand access to the glucose permeation pathway via FLAG-mediated protein engineering.
    Heitmeier MR; Hresko RC; Edwards RL; Prinsen MJ; Ilagan MXG; Odom John AR; Hruz PW
    PLoS One; 2019; 14(5):e0216457. PubMed ID: 31071153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The hexose transporter of Plasmodium falciparum is a worthy drug target.
    Joët T; Krishna S
    Acta Trop; 2004 Feb; 89(3):371-4. PubMed ID: 14744563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasmodial sugar transporters as anti-malarial drug targets and comparisons with other protozoa.
    Slavic K; Krishna S; Derbyshire ET; Staines HM
    Malar J; 2011 Jun; 10():165. PubMed ID: 21676209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triterpenoids as inhibitors of erythrocytic and liver stages of Plasmodium infections.
    Ramalhete C; da Cruz FP; Lopes D; Mulhovo S; Rosário VE; Prudêncio M; Ferreira MJ
    Bioorg Med Chem; 2011 Dec; 19(24):7474-81. PubMed ID: 22071523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An overview of the Plasmodium falciparum hexose transporter and its therapeutic interventions.
    Jiang X
    Proteins; 2022 Oct; 90(10):1766-1778. PubMed ID: 35445447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small-molecule histone methyltransferase inhibitors display rapid antimalarial activity against all blood stage forms in Plasmodium falciparum.
    Malmquist NA; Moss TA; Mecheri S; Scherf A; Fuchter MJ
    Proc Natl Acad Sci U S A; 2012 Oct; 109(41):16708-13. PubMed ID: 23011794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Novel Fluorescence Resonance Energy Transfer-Based Screen in High-Throughput Format To Identify Inhibitors of Malarial and Human Glucose Transporters.
    Kraft TE; Heitmeier MR; Putanko M; Edwards RL; Ilagan MX; Payne MA; Autry JM; Thomas DD; Odom AR; Hruz PW
    Antimicrob Agents Chemother; 2016 Dec; 60(12):7407-7414. PubMed ID: 27736766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bioluminescence Method for
    Azevedo R; Markovic M; Machado M; Franke-Fayard B; Mendes AM; Prudêncio M
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28348156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. D-Glucose concentration is the key factor facilitating liver stage maturation of Plasmodium.
    Itani S; Torii M; Ishino T
    Parasitol Int; 2014 Aug; 63(4):584-90. PubMed ID: 24691399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liver-stage malaria parasites vulnerable to diverse chemical scaffolds.
    Derbyshire ER; Prudêncio M; Mota MM; Clardy J
    Proc Natl Acad Sci U S A; 2012 May; 109(22):8511-6. PubMed ID: 22586124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Probing the Azaaurone Scaffold against the Hepatic and Erythrocytic Stages of Malaria Parasites.
    Carrasco MP; Machado M; Gonçalves L; Sharma M; Gut J; Lukens AK; Wirth DF; André V; Duarte MT; Guedes RC; Dos Santos DJ; Rosenthal PJ; Mazitschek R; Prudêncio M; Moreira R
    ChemMedChem; 2016 Oct; 11(19):2194-2204. PubMed ID: 27538856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasmodium berghei K13 Mutations Mediate
    Simwela NV; Stokes BH; Aghabi D; Bogyo M; Fidock DA; Waters AP
    mBio; 2020 Nov; 11(6):. PubMed ID: 33173001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Studies with the Plasmodium falciparum hexokinase reveal that PfHT limits the rate of glucose entry into glycolysis.
    Tjhin ET; Staines HM; van Schalkwyk DA; Krishna S; Saliba KJ
    FEBS Lett; 2013 Oct; 587(19):3182-7. PubMed ID: 23954294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of Plasmodium vivax hexose transporters and effects of a parasitocidal inhibitor.
    Joët T; Chotivanich K; Silamut K; Patel AP; Morin C; Krishna S
    Biochem J; 2004 Aug; 381(Pt 3):905-9. PubMed ID: 15107012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.